Relative Intelligence · Animal Health

How IDEXX Laboratories (IDXX) compares with the whole market and its popular alternatives
Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on IDXX alone. It places IDXX (IDEXX Laboratories, Inc.) against 19 popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where IDXX stands in the market, and of the alternatives worth a closer look.
Period covered: IDXX's full trading record, from June 1991 through September 2026. All returns include reinvested dividends. Data as of October 20, 2026.
Data as of October 20, 2026. Full tables and charts read best on a larger screen.
On this page12 sections
Key findings
- Right nowIDXX is 27.2% below its high, bear-market territory, while the S&P 500 sits 1.3% below a record. Over the past 6 months, IDXX fell 4.3% while the S&P 500 rose 9.1%. At a glance ↓
- Stock or market?The weakness is IDXX's own: it fell 1.0% over the past 3 months while the animal health ETF IHI (iShares U.S. Medical Devices ETF) rose 7.5%. The S&P 500 rose 3.9%. Its animal health peers did not move as one over the past 3 months: TMO (Thermo Fisher Scientific) rose 30.7%, while QDEL (QuidelOrtho) fell 14.3%.
- Past 1 to 3 yearsIDXX has gone against the market, falling 13.3% over the past year while the S&P 500 rose 15.8%. The same gap shows up over 3 years (30.7% against 89.3%). A ahead of 81% of stocks worth at least $300 million over 10 years, but behind 61% of the stocks worth at least $300 million over 3 years. By year ↓
- Long termIDXX turned $10,000 into $49,800 over the past decade, against $42,100 in the S&P 500. Even so, over 5 years IDXX trailed the index: 13.1% against 81.7%. Growth of $10,000 ↓
- In a crashAcross seven sell-offs, IDXX has typically fallen 1.3 times as far as the S&P 500. In the 2022 bear market, IDXX fell 46.4%, against 24.5% for the S&P 500. That was more than TMO (Thermo Fisher Scientific, 19.8%) but less than ELAN (Elanco Animal Health, 59.5%). Crash tests ↓
- DiversificationAgainst the S&P 500, IDXX has a correlation of 0.68 over 5 years, more closely than 98% of stocks worth at least $300 million. Next to an index fund it is more of the same, not a cushion. IDXX fell in 19 of the 22 months the S&P 500 fell over the past 5 years: it usually fell with it. By year ↓
- Better options
- Nearby categories and themes
- ORLY (O'Reilly Automotive, specialty retail) and LLY (Eli Lilly and Company, pharmaceuticals) earned more than IDXX with less volatility over the past 5 years. ORLY returned 15.9% a year at 23.4% volatility, against a loss of 2.8% a year at 35.7%.
- Versus the S&P 500
- Simply owning the S&P 500 would have done better over the past 5 years: 12.7% a year at 17.1% volatility, against 2.8% at 35.7% for IDXX.
- Whole market
- 1,777 of the 3,633 stocks and funds worth at least $500 million earned more than IDXX with less volatility over the past 5 years, among them AAPL (Apple), GOOG (Alphabet) and MSFT (Microsoft).
How much would $10,000 in IDXX have grown?
This chart tracks a hypothetical $10,000 investment in IDXX over the past 29 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of IDXX over the same span and IDXX's popular alternatives, among those that traded for the entire period. A second view covers the past 5 years, the period the better options further down the page are judged on. It shows not only where each investment ended up but also how smooth or uneven the path was.
- $10,000 invested in IDXX at the end of September 1997 would have grown to $1,246,340 by September 2026, more than the $132,907 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of IDXX, and MNST finished highest, at $45,663,831.
Choose a period
From the end of September 1997 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 27 of the 1,042 stocks and funds worth at least $500 million that traded the whole period ended ahead of IDXX; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- MNST$46M+456,538% total · +33.7% a year
- AAPL$21M+205,249% total · +30.1% a year
- APH$3M+29,926% total · +21.7% a year
- ORLY$2M+22,426% total · +20.5% a year
- GILD$2M+15,614% total · +19.1% a year
- IDXX$1M+12,363% total · +18.1% a year
- DGX$784,474+7,745% total · +16.2% a year
- LH$575,914+5,659% total · +15.0% a year
- TMO$235,386+2,254% total · +11.5% a year
- SPY (S&P 500)$132,907+1,229% total · +9.3% a year
From the end of September 2021 to the end of September 2026. Hover over a fund in the key to pick out its line. 2,851 of the 3,628 stocks and funds worth at least $500 million that traded the whole period ended ahead of IDXX; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- SPY (S&P 500)$19,000+90.0% total · +13.7% a year
- DGX$17,761+77.6% total · +12.2% a year
- LH$13,440+34.4% total · +6.1% a year
- WAT$12,298+23.0% total · +4.2% a year
- TMO$11,986+19.9% total · +3.7% a year
- A$11,334+13.3% total · +2.5% a year
- BDX$10,410+4.1% total · +0.8% a year
- VEEV$9,905−0.9% total · −0.2% a year
- IDXX$8,397−16.0% total · −3.4% a year
- FRPT$4,034−59.7% total · −16.6% a year
IDXX at a glance
This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout. These figures serve as the baseline for every comparison that follows.
- IDXX is still 27.2% below its all-time high.
- IDXX's deepest decline since it began trading in 1991 was 73.1%, from October 2006 to June 2007. It was back at its old high within a month of the low.
- Over 29 full calendar years, IDXX's best was 2020, when it returned 91.4%, and its worst was 1999, when it lost 40.1%. It lost money in six of those years.
The company
- Market value
- $44B
- Industry
- Medical - Diagnostics & Research
- Price history from
- June 1991
Returns
- Past 1 year
- −13.3%total return
- Past 3 years
- +30.7%+9.3% a year
- Past 5 years
- −13.1%−2.8% a year
- Past 10 years
- +398%+17.4% a year
- Best calendar year
- +91.4%2020
- Worst calendar year
- −40.1%1999
- Losing years
- 6 of 29full calendar years
Risk
- Volatility
- 35.7%typical yearly swing, 5 years
- Sharpe ratio
- 0.10return per unit of risk, 5 years
- Worst decline ever
- −73.1%Oct 2006 to Jun 2007
- From its all-time high
- −27.2%below the peak
IDXX against the whole market
Where IDXX ranks among every stock and fund, and what across the market has done better.
How does IDXX rank among all stocks?
This section ranks IDXX on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history. Where the comparisons with its popular alternatives show how IDXX stacks up against its peers, these rankings show where it stands in the market as a whole.
- IDXX's 10-year return ranks in the top 19% of the 2,202 stocks worth at least $300 million with 10 years of history.
Ranked against U.S.-listed stocks worth at least $300M that have enough history for each measure, so the count changes from row to row; smaller stocks are left out. Lower volatility and smaller declines rank higher.
| Measure | IDXX | Rank | Standing |
|---|---|---|---|
| 1-year return | −13.3% | 2,451 of 3,287 | bottom 26% |
| 3-year return | +30.7% | 1,836 of 3,017 | bottom 40% |
| 5-year return | −13.1% | 1,922 of 2,893 | bottom 35% |
| 10-year return | +398% | 421 of 2,202 | top 19% |
| Volatility, 5 years | 35.7% | 1,185 of 2,893 | top 41% |
| Sharpe ratio, 5 years | 0.10 | 2,125 of 2,893 | bottom 28% |
| Worst decline, past 10 years | −54.0% | 618 of 2,187 | top 28% |
What has beaten IDXX on both return and risk?
Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer). IDXX sits where the dashed lines cross. Anything in the green box above and to the left earned more than IDXX with smaller swings, a better trade-off over this period on both counts. Past results are no promise, but a name in the box is worth a closer look.
- 840 stocks and 937 ETFs worth at least $500 million sit in the green region: each earned more than IDXX over the past 5 years with smaller price swings. That is 49% of the 3,633 screened.
- Among those with at least half IDXX's swings, CAH has the best return for its risk: 42.1% a year at 24.7% volatility, 31% less than IDXX's 35.7%, and a Sharpe ratio (return above cash per unit of volatility) of 1.55 against 0.10 for IDXX. MPC earned the most, 51.2% a year, while still swinging less than IDXX (33.4% against 35.7%).
- Among IDXX's popular alternatives, DGX, LH and WAT are in the region. DGX earned 12.3% a year against a loss of 2.8% a year for IDXX, at 22.5% volatility, 37% less than IDXX's 35.7%.
Annual return is the annualized total return with dividends reinvested, and volatility the annualized swing in daily prices, both over 5 years. Labeled dots are the strongest picks from the table below and the names called out above, colored by how close they sit to IDXX; faint dots are 91 more of the 1,777 in the green region (the strongest, one per fund family). 3,633 stocks and funds worth at least $500 million were screened. Hover over a dot for its figures.
- Popular alternatives
- Same and neighboring categories, and shared themes
- The whole market
- Others in the green region
Is there a better investment than IDXX?
Investments that beat IDXX over the past 5 years on return, volatility, drawdowns, consistency, crash losses or fees, from its popular alternatives out to the whole market.
- Among IDXX's popular alternatives, TMO, DGX and LH earned more than IDXX with less volatility over the past 5 years. TMO returned 2.9% a year at 27.8% volatility, against a loss of 2.8% a year at 35.7%.
- Looking beyond its popular alternatives, ORLY (specialty retail) and LLY (pharmaceuticals) earned more than IDXX with less volatility over the past 5 years. ORLY returned 15.9% a year at 23.4% volatility, against a loss of 2.8% a year at 35.7%.
- Simply owning the S&P 500 would have done better over the past 5 years: 12.7% a year at 17.1% volatility, against 2.8% at 35.7% for IDXX.
How this works
The table below lists investments that beat IDXX over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes. It checks IDXX's popular alternatives first, then the rest of its own and neighboring categories, then every stock and fund worth at least $500 million, and shows the strongest few in each group. The full list of those with a higher return and lower volatility than IDXX follows the table.
Annual return is the annualized total return with dividends reinvested. Annual return, volatility and the Sharpe ratio cover 5 years; the worst decline covers the past 10 years. Green marks a better figure than IDXX's. "On the frontier" means no other option shown or tested earned more with less volatility. Funds that hold the same thing are shown once. Beyond the popular alternatives, nothing with more than 1.5× IDXX's volatility counts as better.
These figures cover the past 5 years. Green marks a better figure than IDXX's.
| Investment | Why it is better | Past 5 years | Downside | Long run | Fit | ||||
|---|---|---|---|---|---|---|---|---|---|
| Annual return?higher is better | Volatility?lower is calmer | Sharpe?return per unit of risk | Worst decline?past 10 years | 10Y returntotal | Corr. with IDXX?lower diversifies more | Expenseper year | |||
| −2.8% | 35.7% | 0.10 | −54.0% | +398% | 1.00 | — | |||
| +12.7% | 17.1% | 0.79 | −33.7% | +321% | 0.68 | 0.09% | |||
| Popular alternativesbest 6 shownThe investments people most often weigh against IDXX. 9 of 19 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +2.9% | 27.8% | 0.24 | −40.9% | +366% | 0.49 | — | ||
DGXQuest Diagnostics Incorporated · Medical Diagnostics | Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +12.3% | 22.5% | 0.63 | −36.6% | +243% | 0.42 | — | |
LHLabcorp Holdings Inc. · Medical Diagnostics | Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +7.3% | 23.8% | 0.42 | −46.6% | +184% | 0.63 | — | |
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +4.5% | 33.9% | 0.30 | −44.3% | +182% | 0.54 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +2.6% | 30.6% | 0.24 | −43.2% | +306% | 0.59 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +2.3% | 24.1% | 0.22 | −39.9% | +71.4% | 0.22 | — | ||
| Same and neighboring categories, and shared themesbest 6 shownEverything else in Animal Health and the categories next to it (Life Sciences Tools, Specialty Retail, Medical Diagnostics, Pharmaceuticals), plus IDXX's specific themes. 34 of 62 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periodsSmaller losses in recent crashes | +15.9% | 23.4% | 0.75 | −42.0% | +393% | 0.32 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.18 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +26.1% | 23.4% | 1.11 | −45.1% | +603% | 0.28 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.28 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +17.1% | 20.7% | 0.87 | −26.8% | +226% | 0.42 | — | ||
| Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +8.7% | 35.7% | 0.41 | −28.7% | +257% | 0.33 | — | ||
| The whole marketbest 8 shownEvery other stock and fund worth at least $500 million. 2,256 of 3,552 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periodsSmaller losses in recent crashes | +19.0% | 32.0% | 0.71 | −44.6% | +752% | 0.42 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periodsSmaller losses in recent crashes | +12.5% | 28.2% | 0.56 | −37.1% | +946% | 0.45 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periodsSmaller losses in recent crashes | +17.4% | 22.9% | 0.82 | −31.4% | +685% | 0.55 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periodsSmaller losses in recent crashes | +14.5% | 23.0% | 0.71 | −35.1% | +553% | 0.58 | 0.18% | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periodsSmaller losses in recent crashes | +11.5% | 20.9% | 0.63 | −32.6% | +394% | 0.46 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periodsSmaller losses in recent crashes | +18.4% | 26.0% | 0.78 | −35.1% | +779% | 0.51 | 0.09% | ||
| Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +19.5% | 34.1% | 0.69 | −33.6% | +652% | 0.55 | — | ||
| Similar return, lower volatilityHigher return in most periods | −1.8% | 22.5% | 0.03 | −45.1% | +46.7% | 0.42 | — | ||
What these numbers mean for IDXX
- Annual return
- IDXX lost 2.8% a year over the past 5 years with dividends reinvested, against 12.7% a year for the S&P 500. At that pace, $10,000 became about $8,690. Annual return is the steady yearly rate that would produce the same total result, so investments held over the same span compare fairly. Guide: What is performance and return? →
- Volatility
- IDXX's volatility over the past 5 years was 35.7%, about twice the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, IDXX's return lands within 35.7% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump. Guide: Understanding and measuring risk (volatility) →
- Sharpe ratio
- IDXX's Sharpe ratio over the past 5 years was 0.10, against 0.79 for the S&P 500, so IDXX earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings. Guide: Balancing reward with risk (Sharpe ratio) →
- Worst decline
- IDXX's worst fall from a peak to a low over the past 10 years was 54.0%, against 33.7% for the S&P 500. Losses and gains are not symmetric: climbing back from a 54.0% fall takes a 117% gain. Guide: Market crash risk and tail risk →
- Correlation
- Over the past 5 years, IDXX's monthly returns had a correlation of 0.68 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against IDXX instead: the lower it is, the more that option would diversify a IDXX holding. Guide: Correlation and diversification →
Show all 1,777 stocks and funds worth at least $500 million that earned more than IDXX with less volatility
Out of 3,633 tested over 5 years. The strongest 100 are listed, best first, with funds that hold the same thing listed once.
| # | Investment | Found in | Annual return | Volatility | Sharpe | Worst decline | 10Y return | Corr. with IDXX | Expense |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Whole market | +19.0% | 32.0% | 0.71 | −44.6% | +752% | 0.42 | — | |
| 2 | Whole market | +12.5% | 28.2% | 0.56 | −37.1% | +946% | 0.45 | — | |
| 3 | Whole market | +17.4% | 22.9% | 0.82 | −31.4% | +685% | 0.55 | — | |
| 4 | Whole market | +14.5% | 23.0% | 0.71 | −35.1% | +553% | 0.58 | 0.18% | |
| 5 | Whole market | +11.5% | 20.9% | 0.63 | −32.6% | +394% | 0.46 | — | |
| 6 | Whole market | +18.4% | 26.0% | 0.78 | −35.1% | +779% | 0.51 | 0.09% | |
| 7 | Whole market | +21.3% | 25.6% | 0.89 | −30.3% | +816% | 0.11 | — | |
| 8 | Whole market | +13.9% | 18.5% | 0.80 | −34.0% | +446% | 0.33 | — | |
| 9 | Whole market | +17.3% | 18.2% | 0.97 | −40.0% | +352% | 0.52 | — | |
| 10 | Whole market | +14.8% | 23.6% | 0.71 | −32.8% | +625% | 0.37 | — | |
| 11 | Whole market | +15.8% | 24.6% | 0.72 | −30.7% | +576% | 0.36 | — | |
| 12 | Whole market | +13.1% | 22.4% | 0.67 | −34.5% | +451% | 0.62 | 0.04% | |
| 13 | Whole market | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.24 | — | |
| 14 | Whole market | +18.5% | 28.0% | 0.75 | −38.5% | +1,168% | 0.46 | — | |
| 15 | Whole market | +11.5% | 17.5% | 0.71 | −35.0% | +302% | 0.69 | 0.03% | |
| 16 | Whole market | +12.8% | 16.9% | 0.80 | −34.0% | +324% | 0.68 | 0.03% | |
| 17 | MUSAMurphy USA Inc. · Convenience Stores | Whole market | +26.1% | 31.2% | 0.90 | −35.5% | +706% | -0.05 | — |
| 18 | Whole market | +20.8% | 22.6% | 0.96 | −25.7% | +508% | 0.33 | — | |
| 19 | Whole market | +13.4% | 17.1% | 0.82 | −29.6% | +274% | 0.47 | — | |
| 20 | Same or nearby category | +15.9% | 23.4% | 0.75 | −42.0% | +393% | 0.32 | — | |
| 21 | NHCNational HealthCare Corporation · Medical - Care Facilities | Whole market | +32.0% | 28.5% | 1.12 | −35.3% | +394% | 0.38 | — |
| 22 | Whole market | +17.3% | 24.3% | 0.78 | −43.6% | +537% | 0.46 | — | |
| 23 | TDIVFirst Trust NASDAQ Technology Dividend Index Fund · Technology Equity | Whole market | +16.2% | 21.3% | 0.81 | −32.0% | +388% | 0.55 | 0.50% |
| 24 | Whole market | +12.8% | 22.9% | 0.64 | −36.4% | +429% | 0.42 | — | |
| 25 | DXJWisdomTree Japan Hedged Equity Fund · International Equity | Whole market | +26.6% | 19.1% | 1.34 | −39.1% | +428% | 0.36 | 0.48% |
| 26 | LVHIFranklin International Low Volatility High Dividend Index ETF · International Equity | Whole market | +17.0% | 11.1% | 1.48 | −32.4% | +194% | 0.54 | 0.40% |
| 27 | Whole market | +14.7% | 16.8% | 0.91 | −37.0% | +204% | 0.39 | — | |
| 28 | Whole market | +8.2% | 16.4% | 0.57 | −36.0% | +140% | 0.70 | 0.05% | |
| 29 | Whole market | +12.4% | 23.8% | 0.61 | −41.0% | +541% | 0.46 | — | |
| 30 | Whole market | +21.0% | 23.4% | 0.94 | −42.9% | +242% | 0.23 | — | |
| 31 | Whole market | +16.8% | 26.1% | 0.73 | −42.0% | +374% | 0.41 | — | |
| 32 | Whole market | +38.7% | 25.0% | 1.44 | −38.1% | +586% | 0.11 | — | |
| 33 | PWBInvesco Large Cap Growth ETF · Broad Market | Whole market | +14.8% | 22.2% | 0.74 | −32.4% | +409% | 0.54 | 0.55% |
| 34 | Whole market | +33.8% | 32.2% | 1.07 | −37.5% | +965% | 0.48 | — | |
| 35 | ILCGiShares Morningstar Growth ETF · Broad Market | Whole market | +11.2% | 22.4% | 0.59 | −35.4% | +403% | 0.61 | 0.04% |
| 36 | Whole market | +12.1% | 13.7% | 0.90 | −36.8% | +235% | 0.62 | 0.03% | |
| 37 | Whole market | +19.6% | 24.9% | 0.85 | −24.9% | +266% | 0.23 | — | |
| 38 | Whole market | +22.8% | 24.9% | 0.95 | −30.5% | +200% | 0.16 | — | |
| 39 | Whole market | +9.3% | 16.9% | 0.61 | −35.8% | +153% | 0.72 | 0.03% | |
| 40 | Whole market | +15.8% | 20.0% | 0.84 | −42.0% | +310% | 0.44 | — | |
| 41 | BFCBank First Corporation · Banks - Regional | Whole market | +19.0% | 27.3% | 0.78 | −39.8% | +496% | 0.27 | — |
| 42 | Whole market | +33.6% | 30.6% | 1.10 | −45.7% | +345% | 0.32 | — | |
| 43 | Whole market | +17.7% | 18.9% | 0.96 | −26.4% | +213% | 0.29 | 0.40% | |
| 44 | Whole market | +16.6% | 30.5% | 0.66 | −41.1% | +151% | 0.17 | — | |
| 45 | Whole market | +33.7% | 29.4% | 1.14 | −47.6% | +474% | 0.31 | — | |
| 46 | Whole market | +16.6% | 31.4% | 0.65 | −44.3% | +398% | 0.43 | — | |
| 47 | Whole market | +15.7% | 20.4% | 0.82 | −42.6% | +248% | 0.28 | — | |
| 48 | Whole market | +9.9% | 33.7% | 0.45 | −33.4% | +424% | 0.42 | — | |
| 49 | Whole market | +22.6% | 29.1% | 0.85 | −41.6% | +521% | -0.02 | — | |
| 50 | EQLALPS Equal Sector Weight ETF · Broad Market | Whole market | +13.5% | 14.5% | 0.94 | −34.2% | +387% | 0.71 | 0.19% |
| 51 | Whole market | +19.2% | 21.6% | 0.93 | −47.3% | +395% | 0.53 | — | |
| 52 | Whole market | +6.8% | 17.6% | 0.47 | −39.4% | +198% | 0.71 | 0.03% | |
| 53 | Whole market | +14.4% | 29.9% | 0.60 | −37.9% | +755% | 0.27 | — | |
| 54 | Whole market | +10.4% | 14.1% | 0.78 | −31.7% | +258% | 0.71 | 0.04% | |
| 55 | Whole market | +22.4% | 22.3% | 1.02 | −46.3% | +347% | 0.29 | — | |
| 56 | Whole market | +22.7% | 27.7% | 0.88 | −40.5% | +955% | 0.47 | — | |
| 57 | Whole market | +24.2% | 22.8% | 1.07 | −32.4% | +406% | 0.35 | — | |
| 58 | Whole market | +9.7% | 14.3% | 0.72 | −33.4% | +252% | 0.58 | 0.06% | |
| 59 | Whole market | +9.8% | 25.2% | 0.50 | −39.4% | +60.7% | 0.17 | — | |
| 60 | Whole market | +26.3% | 24.9% | 1.07 | −41.6% | +654% | 0.33 | — | |
| 61 | Whole market | +12.9% | 19.9% | 0.71 | −46.9% | +187% | 0.63 | — | |
| 62 | Whole market | +12.2% | 29.0% | 0.54 | −37.5% | +464% | 0.40 | — | |
| 63 | Whole market | +7.1% | 22.9% | 0.42 | −38.7% | +295% | 0.55 | — | |
| 64 | Whole market | +6.2% | 20.6% | 0.40 | −42.0% | +179% | 0.69 | 0.03% | |
| 65 | Whole market | +7.1% | 27.1% | 0.39 | −43.9% | +313% | 0.59 | — | |
| 66 | Whole market | +17.2% | 24.9% | 0.77 | −30.4% | +285% | 0.46 | — | |
| 67 | Whole market | +11.1% | 24.2% | 0.56 | −36.7% | +204% | 0.09 | — | |
| 68 | Whole market | +10.3% | 16.2% | 0.69 | −34.2% | +223% | 0.73 | 0.06% | |
| 69 | Whole market | +11.3% | 18.8% | 0.67 | −38.4% | +170% | 0.11 | — | |
| 70 | Whole market | +16.5% | 23.1% | 0.78 | −48.4% | +808% | 0.49 | — | |
| 71 | Whole market | +6.8% | 19.4% | 0.44 | −38.7% | +122% | 0.51 | 0.09% | |
| 72 | Whole market | +5.2% | 17.5% | 0.38 | −36.4% | +102% | 0.54 | 0.06% | |
| 73 | Whole market | +11.2% | 20.8% | 0.62 | −37.4% | +319% | 0.34 | — | |
| 74 | Whole market | +17.4% | 29.1% | 0.70 | −46.4% | +426% | 0.58 | — | |
| 75 | Whole market | +2.7% | 22.9% | 0.23 | −41.2% | +55.8% | 0.21 | — | |
| 76 | Same or nearby category | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.18 | — | |
| 77 | Whole market | +5.5% | 21.5% | 0.36 | −30.1% | +89.8% | 0.45 | — | |
| 78 | PJULInnovator U.S. Equity Power Buffer ETF · Broad Market | Whole market | +10.5% | 8.6% | 1.20 | −18.2% | — | 0.69 | 0.79% |
| 79 | Whole market | +8.2% | 16.1% | 0.57 | −39.0% | +211% | 0.72 | 0.20% | |
| 80 | Whole market | +9.3% | 19.2% | 0.56 | −30.1% | +344% | 0.33 | — | |
| 81 | Whole market | +11.8% | 22.6% | 0.61 | −39.2% | +118% | 0.47 | — | |
| 82 | FJANFT Vest U.S. Equity Buffer ETF - January · Multi-Asset | Whole market | +11.1% | 10.5% | 1.05 | −13.6% | — | 0.63 | 0.85% |
| 83 | Whole market | +19.7% | 23.2% | 0.90 | −48.8% | +292% | 0.31 | — | |
| 84 | Whole market | +7.5% | 18.0% | 0.50 | −37.4% | +132% | 0.28 | — | |
| 85 | Whole market | +12.4% | 20.2% | 0.68 | −32.9% | +185% | 0.31 | — | |
| 86 | Whole market | +17.0% | 26.2% | 0.73 | −41.4% | +356% | 0.14 | — | |
| 87 | Whole market | +8.3% | 23.3% | 0.46 | −40.5% | +446% | 0.49 | — | |
| 88 | Whole market | +14.4% | 22.1% | 0.72 | −42.7% | +481% | 0.49 | — | |
| 89 | Whole market | +13.3% | 30.0% | 0.57 | −39.2% | +711% | 0.47 | — | |
| 90 | Whole market | +14.7% | 17.5% | 0.87 | −34.7% | — | 0.68 | 0.26% | |
| 91 | Whole market | +10.8% | 21.9% | 0.58 | −41.6% | +160% | 0.31 | — | |
| 92 | Whole market | +10.9% | 24.2% | 0.55 | −44.4% | +516% | 0.29 | — | |
| 93 | Whole market | +7.2% | 19.2% | 0.46 | −29.0% | +68.8% | 0.25 | — | |
| 94 | Whole market | +5.4% | 21.8% | 0.35 | −34.3% | +240% | 0.60 | — | |
| 95 | Whole market | +4.9% | 22.4% | 0.33 | −41.7% | +194% | 0.67 | 0.05% | |
| 96 | Whole market | +6.7% | 21.4% | 0.41 | −37.9% | +208% | 0.58 | — | |
| 97 | Whole market | +6.7% | 24.1% | 0.39 | −43.7% | +176% | 0.62 | — | |
| 98 | Whole market | +7.5% | 11.0% | 0.71 | −13.7% | — | 0.67 | 0.35% | |
| 99 | Whole market | +5.9% | 26.9% | 0.35 | −42.0% | +383% | 0.64 | — | |
| 100 | CBOECboe Global Markets, Inc. · Capital Markets | Whole market | +21.5% | 25.1% | 0.91 | −43.2% | +463% | 0.28 | — |
IDXX against its popular alternatives
The investments people most often weigh against IDXX, compared period by period and year by year.
How do IDXX's risk and return compare with its alternatives?
This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings. Investments toward the upper left earned more for a smoother ride, and those toward the lower right earned less for a rougher one. The dashed lines cross at IDXX, which divides the map into what did better or worse on each measure.
- Eight of the 19 popular alternatives, led by DGX, LH and WAT, were both more rewarding and calmer than IDXX over the past 5 years, earning a higher annual return with lower volatility.
- Over the past 5 years, IDXX returned -2.8% a year, less than the S&P 500's 12.7%, with higher volatility (35.7% against 17.1%).
Green points earned more than IDXX with less volatility; red points earned less with more. Hover over a point for its figures. Total returns with dividends reinvested, annualized.
All figures
| Investment | Annual return | Volatility |
|---|---|---|
| SPY S&P 500State Street SPDR S&P 500 ETF | +12.7% | 17.1% |
| DGX Quest Diagnostics Incorporated | +12.3% | 22.5% |
| LH Labcorp Holdings Inc. | +7.3% | 23.8% |
| WAT Waters Corporation | +4.5% | 33.9% |
| TMO Thermo Fisher Scientific Inc. | +2.9% | 27.8% |
| A Agilent Technologies, Inc. | +2.6% | 30.6% |
| BDX Becton, Dickinson and Company | +2.3% | 24.1% |
| HSIC Henry Schein, Inc. | +1.5% | 25.4% |
| VEEV Veeva Systems Inc. | −0.1% | 39.6% |
| ABT Abbott Laboratories | −1.7% | 23.1% |
| IDXX This pageIDEXX Laboratories, Inc. | −2.8% | 35.7% |
| DHR Danaher Corporation | −3.8% | 29.1% |
| ELAN Elanco Animal Health Incorporated | −7.6% | 45.8% |
| BIO Bio-Rad Laboratories, Inc. | −13.9% | 37.9% |
| FRPT Freshpet, Inc. | −15.3% | 50.9% |
| ZTS Zoetis Inc. | −16.3% | 29.6% |
| CHWY Chewy, Inc. | −20.1% | 61.0% |
| NEOG Neogen Corporation | −22.2% | 50.8% |
| TRUP Trupanion, Inc. | −22.8% | 71.4% |
| QDEL QuidelOrtho Corporation | −35.9% | 63.7% |
| WOOF Petco Health and Wellness Company, Inc. | −36.9% | 73.8% |
Has IDXX consistently beaten its popular alternatives?
This section compares IDXX with the investments people most often weigh against it, checking each one over eight periods from one month to ten years. Counting how often an alternative earned more than IDXX helps separate lasting outperformance from a single strong stretch.
- Six of the 19 popular alternatives, led by VEEV, TMO and A, outperformed IDXX in at least 3 of 5 short-term and 2 of 3 long-term timeframes.
- VEEV outperformed IDXX in every long-term period and in all but one short-term period, the most consistent record in the group.
- DGX, LH and WAT earned more for the risk they took than IDXX (a higher Sharpe ratio) and fell less in their worst decline of the past 10 years.
A green cell means the alternative earned more than IDXX over that period. "Qualified" marks those that did so in at least 3 of 5 short-term periods and 2 of 3 long-term periods.
| Investment | Periods outperformed | Short term | Long term | Risk · 5 years | Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Volatilitylower is calmer | Sharpehigher is better | Worst declinepast 10 years | Expense | Assets | Overlapsame sectors | ||
| IDXX IDEXX Laboratories, Inc. (this page) | — | +8.3% | −1.0% | −4.3% | −16.7% | −13.3% | +30.7% | −13.1% | +398% | 35.7% | 0.10 | −54.0% | — | $44B | — |
| VEEV QualifiedVeeva Systems Inc. | 5/5 short3/3 longAll-weather | +22.0% | +61.4% | +88.7% | +45.2% | +11.5% | +59.0% | −0.4% | +715% | 39.6% | 0.19 | −55.7% | — | $52B | — |
| TMO QualifiedThermo Fisher Scientific Inc. | 4/5 short2/3 long | +4.3% | +30.7% | +30.9% | +16.3% | +26.8% | +49.5% | +15.1% | +366% | 27.8% | 0.24 | −40.9% | — | $254B | — |
| A QualifiedAgilent Technologies, Inc. | 4/5 short2/3 long | +7.1% | +33.1% | +43.6% | +26.4% | +22.0% | +62.1% | +13.8% | +306% | 30.6% | 0.24 | −43.2% | — | $49B | — |
| DGX QualifiedQuest Diagnostics Incorporated | 4/5 short2/3 long | −2.9% | +14.5% | +21.6% | +38.6% | +26.5% | +103% | +78.5% | +243% | 22.5% | 0.63 | −36.6% | — | $26B | — |
| LH QualifiedLabcorp Holdings Inc. | 4/5 short2/3 long | +0.7% | +15.0% | +20.6% | +29.3% | +12.2% | +67.4% | +42.4% | +184% | 23.8% | 0.42 | −46.6% | — | $26B | — |
| WAT QualifiedWaters Corporation | 4/5 short2/3 long | +4.5% | +23.9% | +31.9% | +15.9% | +29.0% | +74.6% | +24.4% | +182% | 33.9% | 0.30 | −44.3% | — | $43B | — |
| FRPT Packaged FoodsFreshpet, Inc. | 4/5 short1/3 long | +7.6% | +16.0% | −3.0% | +9.8% | +27.7% | +19.5% | −56.3% | +630% | 50.9% | -0.07 | −79.0% | — | $3.2B | — |
| BDX Medical - Instruments & SuppliesBecton, Dickinson and Company | 4/5 short1/3 long | +7.2% | +26.2% | +23.7% | +28.9% | +32.3% | +1.6% | +12.2% | +71.4% | 24.1% | 0.22 | −39.9% | — | $53B | — |
| ABT Medical - DevicesAbbott Laboratories | 3/5 short1/3 long | +0.3% | +1.6% | +8.4% | −15.3% | −18.7% | +13.0% | −8.0% | +204% | 23.1% | 0.04 | −39.6% | — | $178B | — |
| HSIC Medical - DistributionHenry Schein, Inc. | 3/5 short1/3 long | −0.6% | −1.8% | +7.0% | +10.2% | +32.5% | +24.0% | +7.9% | +41.3% | 25.4% | 0.19 | −41.4% | — | $9.4B | — |
| ELAN Drug Manufacturers - Specialty & GenericElanco Animal Health Incorporated | 2/5 short1/3 long | +1.2% | −9.7% | −4.1% | +0.8% | +4.5% | +148% | −32.6% | — | 45.8% | 0.05 | −78.0% | — | $11B | — |
| DHR Medical - Diagnostics & ResearchDanaher Corporation | 4/5 short0/3 long | +4.0% | +11.6% | +15.0% | −2.2% | +8.3% | +10.8% | −17.6% | +232% | 29.1% | 0.01 | −43.8% | — | $157B | — |
| BIO Medical - DevicesBio-Rad Laboratories, Inc. | 4/5 short0/3 long | −6.0% | +17.4% | +16.9% | +16.1% | +10.1% | +14.1% | −52.5% | +115% | 37.9% | -0.21 | −73.8% | — | $9.5B | — |
| NEOG Medical - DevicesNeogen Corporation | 4/5 short0/3 long | −13.9% | +17.1% | +21.7% | +67.4% | +99.0% | −22.1% | −71.5% | −41.0% | 50.8% | -0.24 | −90.9% | — | $2.6B | — |
| TRUP Insurance - Property & CasualtyTrupanion, Inc. | 3/5 short0/3 long | +15.0% | +7.6% | −0.4% | −22.7% | −34.7% | +26.6% | −72.6% | +77.3% | 71.4% | 0.00 | −87.3% | — | $1.3B | — |
| ZTS Drug Manufacturers - Specialty & GenericZoetis Inc. | 2/5 short0/3 long | +12.2% | +5.0% | −34.3% | −35.4% | −43.8% | −50.1% | −59.0% | +70.3% | 29.6% | -0.45 | −70.5% | — | $33B | — |
| QDEL Medical - SpecialtiesQuidelOrtho Corporation | 2/5 short0/3 long | +30.8% | −14.3% | +10.2% | −50.6% | −51.0% | −78.8% | −89.2% | −33.1% | 63.7% | -0.38 | −96.7% | — | $974M | — |
| CHWY Specialty RetailChewy, Inc. | 0/5 short0/3 long | +5.0% | −2.1% | −25.4% | −35.7% | −42.5% | +28.2% | −67.3% | — | 61.0% | -0.07 | −87.4% | — | $8.7B | — |
| WOOF Specialty RetailPetco Health and Wellness Company, Inc. | 0/5 short0/3 long | −1.7% | −14.0% | −23.1% | −18.2% | −36.7% | −32.3% | −90.0% | — | 73.8% | -0.27 | −94.9% | — | $667M | — |
How did IDXX do year by year?
This table shows each investment's total return in every full calendar year since 1997, along with where IDXX ranked among its popular alternatives each year. Annual results reveal how consistently each one kept pace with IDXX and how far its good and bad years diverged, detail that multiyear averages tend to smooth over.
- Ranked against its popular alternatives each year, IDXX finished in the top quarter in 12 of 29 years and in the bottom quarter in five. In 2025, it ranked 2 of 20.
- IDXX finished ahead of the S&P 500 in 21 of its 29 full calendar years.
- Among its popular alternatives, FRPT came out ahead of IDXX most often, in six of the 11 years both traded.
Newest year first. Green marks a year in which the fund came out ahead of IDXX; gray means the two finished within a fraction of a point. The rank row places IDXX among the alternatives that traded the full year; dark green is the top quarter and red the bottom quarter.
| Investment | Years ahead of IDXX | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDXX This pageIDEXX Laboratories, Inc. | — | +63.6% | −25.5% | +36.0% | −38.0% | +31.7% | +91.4% | +40.4% | +18.9% | +33.4% | +60.8% | −1.6% | +39.4% | +14.6% | +20.6% | +11.2% | +29.5% | +48.2% | −38.5% | +47.9% | +10.2% | +31.9% | +18.0% | +40.9% | +15.2% | +29.6% | +36.5% | −40.1% | +69.1% | −11.6% |
| Rank among alternatives | Top quarter in 12 of 29 | 2 of 20 | 18 of 20 | 2 of 20 | 13 of 20 | 8 of 19 | 6 of 19 | 9 of 18 | 5 of 17 | 10 of 17 | 2 of 17 | 15 of 17 | 1 of 15 | 11 of 13 | 5 of 13 | 2 of 13 | 3 of 13 | 3 of 13 | 9 of 13 | 3 of 13 | 11 of 13 | 3 of 13 | 7 of 13 | 8 of 13 | 3 of 13 | 4 of 12 | 8 of 12 | 10 of 11 | 3 of 11 | 8 of 11 |
| SPY S&P 500State Street SPDR S&P 500 ETF | 8 of 29 | +17.7% | +24.9% | +26.2% | −18.2% | +28.7% | +18.3% | +31.2% | −4.6% | +21.7% | +12.0% | +1.2% | +13.5% | +32.3% | +16.0% | +1.9% | +15.1% | +26.4% | −36.8% | +5.1% | +15.9% | +4.8% | +10.7% | +28.2% | −21.6% | −11.7% | −9.8% | +20.4% | +28.7% | +33.5% |
| VEEV Veeva Systems Inc. | 6 of 12 | +6.2% | +9.2% | +19.3% | −36.8% | −6.2% | +93.5% | +57.5% | +61.6% | +35.8% | +41.1% | +9.2% | −17.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| TMO Thermo Fisher Scientific Inc. | 13 of 29 | +11.8% | −1.7% | −3.4% | −17.3% | +43.5% | +43.7% | +45.6% | +18.2% | +35.0% | −0.1% | +13.8% | +13.1% | +75.8% | +43.2% | −18.8% | +16.1% | +40.0% | −40.9% | +27.4% | +50.3% | −0.2% | +19.8% | +25.3% | −15.7% | +5.6% | +98.2% | −11.4% | −61.5% | +6.7% |
| A Agilent Technologies, Inc. | 11 of 26 | +1.9% | −2.7% | −6.4% | −5.5% | +35.5% | +39.8% | +27.5% | +1.7% | +48.3% | +10.2% | +3.5% | +0.8% | +41.1% | +18.4% | −15.7% | +33.4% | +98.7% | −57.4% | +5.4% | +11.1% | +38.1% | −17.6% | +62.8% | −37.0% | −47.9% | −29.2% | — | — | — |
| DGX Quest Diagnostics Incorporated | 9 of 29 | +17.2% | +11.8% | −10.1% | −7.4% | +47.9% | +14.1% | +31.1% | −13.8% | +9.1% | +31.9% | +8.4% | +28.0% | −6.2% | +1.5% | +8.4% | −10.0% | +17.2% | −1.1% | +0.6% | +3.7% | +8.5% | +31.6% | +28.5% | −20.7% | +1.0% | +364% | +72.0% | +5.4% | +11.3% |
| LH Labcorp Holdings Inc. | 10 of 29 | +10.6% | +2.2% | +13.8% | −24.4% | +54.4% | +20.3% | +33.9% | −20.8% | +24.3% | +3.8% | +14.6% | +18.1% | +5.5% | +0.8% | −2.2% | +17.5% | +16.2% | −14.7% | +2.8% | +36.5% | +8.1% | +34.8% | +59.0% | −42.5% | −8.1% | +377% | +168% | −21.6% | −39.0% |
| WAT Waters Corporation | 14 of 29 | +2.4% | +12.7% | −3.9% | −8.1% | +50.6% | +5.9% | +23.9% | −2.4% | +43.8% | −0.1% | +19.4% | +12.7% | +14.8% | +17.6% | −4.7% | +25.4% | +69.1% | −53.6% | +61.5% | +29.5% | −19.2% | +41.1% | +52.3% | −43.8% | −53.6% | +215% | +21.5% | +129% | +25.6% |
| FRPT Freshpet, Inc. | 6 of 11 | −58.9% | +70.7% | +64.4% | −44.6% | −32.9% | +140% | +83.7% | +69.7% | +86.7% | +19.6% | −50.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BDX Becton, Dickinson and Company | 7 of 24 | −12.5% | −5.3% | −2.7% | +5.1% | +1.9% | −6.8% | +22.2% | +6.6% | +31.2% | +9.2% | +12.6% | +28.3% | +44.3% | +7.3% | −9.7% | +9.4% | +17.6% | −16.9% | +20.7% | +18.3% | +7.2% | +39.8% | +35.6% | −6.4% | — | — | — | — | — |
| ABT Abbott Laboratories | 11 of 29 | +12.9% | +4.8% | +2.3% | −20.7% | +30.5% | +28.1% | +22.1% | +29.1% | +52.0% | −12.3% | +1.9% | +20.1% | +24.3% | +20.3% | +21.8% | −8.3% | +4.6% | −2.5% | +18.1% | +26.9% | −13.5% | +9.2% | +19.3% | −26.8% | +17.0% | +35.8% | −24.7% | +51.9% | +31.4% |
| HSIC Henry Schein, Inc. | 10 of 29 | +9.2% | −8.6% | −5.2% | +3.0% | +16.0% | +0.2% | +8.3% | +12.3% | −7.9% | −4.1% | +16.2% | +19.1% | +42.1% | +24.8% | +5.0% | +16.7% | +43.4% | −40.2% | +25.4% | +12.3% | +25.4% | +3.0% | +50.2% | +21.5% | +6.9% | +160% | −70.2% | +27.8% | +1.8% |
| ELAN Elanco Animal Health Incorporated | 2 of 7 | +86.9% | −18.7% | +21.9% | −56.9% | −7.5% | +4.1% | −6.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| DHR Danaher Corporation | 14 of 29 | +0.4% | −0.4% | −1.2% | −19.0% | +48.6% | +45.4% | +49.5% | +11.8% | +20.0% | +73.2% | +9.3% | +11.6% | +38.3% | +19.1% | −0.1% | +25.7% | +33.0% | −35.4% | +21.3% | +30.1% | −2.7% | +25.3% | +39.7% | +9.1% | −11.7% | +41.5% | −11.0% | +72.4% | +35.2% |
| BIO Bio-Rad Laboratories, Inc. | 10 of 29 | −7.8% | +1.7% | −23.2% | −44.4% | +29.6% | +57.5% | +59.4% | −2.7% | +30.9% | +31.5% | +15.0% | −2.5% | +17.7% | +9.4% | −7.5% | +7.7% | +28.1% | −27.3% | +25.6% | +26.1% | +14.1% | −0.5% | +49.0% | +22.3% | +99.1% | +36.0% | +11.3% | −19.6% | −12.9% |
| NEOG Neogen Corporation | 11 of 29 | −42.4% | −39.6% | +32.0% | −66.5% | +14.5% | +21.5% | +14.5% | −7.6% | +24.6% | +16.8% | +14.0% | +8.5% | +51.3% | +47.9% | −25.3% | +73.9% | +41.8% | −6.1% | +79.3% | +6.0% | −7.5% | +14.5% | +65.4% | −17.4% | +123% | +54.8% | −25.7% | −37.8% | +58.1% |
| TRUP Trupanion, Inc. | 5 of 11 | −22.5% | +58.0% | −35.8% | −64.0% | +10.3% | +220% | +47.1% | −13.0% | +88.6% | +59.0% | +40.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ZTS Zoetis Inc. | 5 of 12 | −21.8% | −16.6% | +35.9% | −39.5% | +48.3% | +25.8% | +55.7% | +19.5% | +35.6% | +12.7% | +12.1% | +32.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| QDEL QuidelOrtho Corporation | 12 of 29 | −35.9% | −39.6% | −14.0% | −36.5% | −24.9% | +139% | +53.7% | +12.6% | +102% | +1.0% | −26.7% | −6.4% | +65.5% | +23.4% | +4.7% | +4.9% | +5.4% | −32.9% | +43.0% | +26.6% | +112% | −52.8% | +211% | −55.0% | +52.9% | −26.9% | +182% | −32.8% | −19.3% |
| CHWY Chewy, Inc. | 2 of 6 | −1.3% | +41.7% | −36.3% | −37.1% | −34.4% | +210% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| WOOF Petco Health and Wellness Company, Inc. | 1 of 4 | −26.3% | +20.6% | −66.7% | −52.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Risk and diversification
How IDXX has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.
What were IDXX's worst declines?
A drawdown is the decline from a peak to the lowest point before a new high. This section presents IDXX's five deepest drawdowns since it began trading in 1991, alongside the S&P 500's return over the same dates, and how long each took to recover. Together, these figures show how much an investor could have lost and how long it took to get back to even.
- In all five of IDXX's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: IDXX fell 73.1% from October 2006 to June 2007, while the S&P 500 rose 12.1%.
- The slowest recovery came after IDXX fell 54.0% from August 2021 to October 2022; it did not regain that peak until November 2025, three years later.
Green means IDXX fell less than the S&P 500 over the same dates. Based on daily closing prices with dividends reinvested.
| During | IDXX fell | S&P 500, same dates | Peak | Low | Time to the low | Back at the peak | Time to recover |
|---|---|---|---|---|---|---|---|
| No named crash | −73.1% | +12.1% | Oct 2006 | Jun 2007 | 8 months | Jun 2007 | Under a month |
| No named crash | −62.9% | +22.2% | Feb 1996 | Apr 1997 | 14 months | Nov 1998 | 19 months |
| 2008 financial crisis | −57.3% | −47.1% | Nov 2007 | Nov 2008 | 12 months | Apr 2010 | 17 months |
| 2022 bear market | −54.0% | −17.6% | Aug 2021 | Oct 2022 | 14 months | Nov 2025 | 3.1 years |
| No named crash | −47.5% | +5.5% | Jun 1999 | Jan 2000 | 7 months | Feb 2000 | 1 month |
How did IDXX do in stock market crashes?
This section measures how far IDXX, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000. A smaller decline means an investment held up better, and comparing results across crashes shows whether that resilience was consistent or a one-off.
- IDXX fell further than the S&P 500 in nine of the ten crashes it has traded through. The clearest case was the 2022 bear market, when IDXX fell 46.4% and the S&P 500 fell 24.5%.
- Among its popular alternatives, HSIC held up best, falling less than IDXX in nine of the ten crashes they both traded through.
Newest crash first. Each figure is the fund's deepest fall within the crash window; green means a smaller fall than IDXX.
| Investment | Held up better | 2023 regional bank crisisMar 2023 | 2022 bear marketJan 2022 | Covid crashFeb 2020 | Late-2018 sell-offSep 2018 | February 2018 volatility shockFeb 2018 | 2015 China and oil sell-offAug 2015 | 2011 euro debt crisisJul 2011 | 2010 flash crashMay 2010 | 2008 financial crisisOct 2007 | Dot-com bustMar 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IDXX This pageIDEXX Laboratories, Inc. | — | −5.7% | −46.4% | −37.1% | −29.4% | −9.2% | −17.8% | −24.0% | −3.6% | −57.3% | −32.6% |
| SPY S&P 500State Street SPDR S&P 500 ETF | 9 of 10 | −3.4% | −24.5% | −33.7% | −19.3% | −6.5% | −12.8% | −17.9% | −1.5% | −55.2% | −47.5% |
| VEEV Veeva Systems Inc. | 4 of 6 | −4.6% | −40.0% | −26.7% | −26.5% | −9.5% | −28.9% | — | — | — | — |
| TMO Thermo Fisher Scientific Inc. | 6 of 10 | −2.4% | −19.8% | −24.8% | −17.2% | −8.7% | −14.7% | −24.4% | −3.6% | −53.9% | −41.8% |
| A Agilent Technologies, Inc. | 4 of 10 | −3.7% | −25.3% | −25.8% | −16.1% | −8.7% | −17.6% | −37.3% | −4.2% | −67.6% | −92.4% |
| DGX Quest Diagnostics Incorporated | 8 of 10 | −2.7% | −22.3% | −35.0% | −26.1% | −6.5% | −17.8% | −19.3% | −1.0% | −29.2% | −46.6% |
| LH Labcorp Holdings Inc. | 6 of 10 | −4.7% | −29.6% | −45.5% | −30.6% | −3.8% | −19.5% | −18.4% | −1.4% | −33.5% | −63.1% |
| WAT Waters Corporation | 5 of 10 | −1.6% | −26.3% | −25.3% | −14.7% | −9.7% | −16.6% | −26.4% | −3.4% | −60.7% | −80.1% |
| FRPT Freshpet, Inc. | 2 of 6 | −10.1% | −65.9% | −42.7% | −27.4% | −3.7% | −63.1% | — | — | — | — |
| BDX Becton, Dickinson and Company | 8 of 9 | −2.0% | −19.7% | −21.8% | −20.4% | −10.8% | −15.1% | −18.3% | −1.6% | −34.1% | — |
| ABT Abbott Laboratories | 7 of 10 | −2.5% | −27.9% | −29.7% | −11.7% | −8.8% | −27.4% | −11.5% | −0.5% | −22.3% | −45.7% |
| HSIC Henry Schein, Inc. | 9 of 10 | −1.0% | −28.5% | −41.4% | −17.7% | −4.7% | −12.8% | −18.3% | −3.0% | −47.8% | −25.6% |
| ELAN Elanco Animal Health Incorporated | 1 of 4 | −12.7% | −59.5% | −46.5% | −18.1% | — | — | — | — | — | — |
| DHR Danaher Corporation | 8 of 10 | −3.2% | −22.8% | −25.9% | −13.4% | −9.8% | −14.0% | −21.8% | −0.6% | −45.7% | −33.7% |
| BIO Bio-Rad Laboratories, Inc. | 7 of 10 | −1.9% | −45.3% | −21.8% | −29.7% | −8.0% | −18.1% | −25.4% | −0.5% | −50.9% | −29.1% |
| NEOG Neogen Corporation | 4 of 10 | −6.4% | −73.4% | −25.8% | −41.0% | −7.5% | −23.5% | −31.4% | −2.1% | −41.7% | −54.5% |
| TRUP Trupanion, Inc. | 2 of 6 | −13.0% | −57.8% | −29.4% | −37.4% | −7.0% | −25.3% | — | — | — | — |
| ZTS Zoetis Inc. | 5 of 6 | −4.2% | −34.9% | −35.7% | −16.7% | −6.9% | −18.9% | — | — | — | — |
| QDEL QuidelOrtho Corporation | 6 of 10 | −3.9% | −48.2% | −17.3% | −34.9% | −7.4% | −30.6% | −19.1% | −0.5% | −56.6% | −80.2% |
| CHWY Chewy, Inc. | 2 of 3 | −3.7% | −57.1% | −26.2% | — | — | — | — | — | — | — |
| WOOF Petco Health and Wellness Company, Inc. | 0 of 2 | −8.7% | −52.7% | — | — | — | — | — | — | — | — |
How closely does IDXX move with the S&P 500?
Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell. An investment that captures more of the gains than the losses has compounded ahead of the market over time. This section compares IDXX with its popular alternatives on both measures, and on beta (how strongly each has moved with the market), over the past 10 years.
- VEEV took just 89% of the S&P 500's losses, against 145% for IDXX, while still keeping 113% of its gains.
- Over the past 10 years, IDXX captured 128% of the S&P 500's gains in rising months and 145% of its losses in falling months, with a beta of 1.27. It amplified the market's moves in both directions.
- Seven of the 16 popular alternatives had a higher capture ratio (upside capture divided by downside capture) than IDXX's 0.88, led by DGX, VEEV and DHR.
Monthly total returns over the past 10 years, measured against SPY. 100% capture or a beta of 1.00 means moving in line with the S&P 500. Green marks a better figure than IDXX's: more upside, less downside or a higher capture ratio. Sorted by capture ratio.
| Investment | Upside capture | Downside capture | Capture ratio | Beta |
|---|---|---|---|---|
| IDXX This pageIDEXX Laboratories, Inc. | 128% | 145% | 0.88 | 1.27 |
| DGX Quest Diagnostics Incorporated | 69% | 54% | 1.28 | 0.80 |
| VEEV Veeva Systems Inc. | 113% | 89% | 1.26 | 0.87 |
| DHR Danaher Corporation | 84% | 84% | 1.01 | 0.75 |
| TMO Thermo Fisher Scientific Inc. | 104% | 104% | 1.00 | 0.81 |
| ABT Abbott Laboratories | 76% | 79% | 0.96 | 0.64 |
| FRPT Freshpet, Inc. | 147% | 157% | 0.94 | 1.24 |
| LH Labcorp Holdings Inc. | 81% | 91% | 0.89 | 0.97 |
| A Agilent Technologies, Inc. | 120% | 141% | 0.85 | 1.13 |
| WAT Waters Corporation | 107% | 139% | 0.77 | 1.01 |
| BIO Bio-Rad Laboratories, Inc. | 104% | 146% | 0.71 | 0.99 |
| BDX Becton, Dickinson and Company | 53% | 77% | 0.69 | 0.48 |
| ZTS Zoetis Inc. | 64% | 101% | 0.64 | 0.72 |
| HSIC Henry Schein, Inc. | 72% | 124% | 0.59 | 0.85 |
| TRUP Trupanion, Inc. | 129% | 223% | 0.58 | 1.67 |
| NEOG Neogen Corporation | 104% | 231% | 0.45 | 1.17 |
| QDEL QuidelOrtho Corporation | 22% | 95% | 0.24 | 0.38 |
What diversifies IDXX?
Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions). This section lists large ETFs and stocks whose returns have had a low correlation with IDXX's. Because such investments tend not to fall at the same time, pairing IDXX with them can reduce a portfolio's overall swings.
- Moving a fifth of the money in IDXX into MCK would have cut the portfolio's volatility by 17% over the past 5 years and raised its annual return (-3.4% for IDXX alone, +4.6% for the mix).
- Among large ETFs, DXJ, EMLP and HDV have moved largely independently of IDXX over the past 5 years, with correlations of 0.48 or lower, and each still earned a positive 5-year return.
- CAH made money in four of the six calendar years in which IDXX lost money.
Only ETFs with at least $1.0B in assets and stocks worth at least $10B, with a correlation below 0.5 over the past 5 years and a positive return, are included, ranked by Sharpe ratio; funds that hold the same thing are shown once. The year columns are the years in which IDXX lost money. The last two columns show a portfolio that is 80% IDXX and 20% the other investment, rebalanced monthly.
ETFs
| Investment | Correlation | 5Y return | Sharpe | 2024 | 2022 | 2015 | 2008 | 1999 | 1997 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IDXX IDEXX Laboratories, Inc. (this page) | 1.00 | −13.1% | 0.10 | −25.5% | −38.0% | −1.6% | −38.5% | −40.1% | −11.6% | 35.6% | −3.4% |
| DXJ InternationalWisdomTree Japan Hedged Equity Fund | 0.36 | +225% | 1.34 | +29.8% | +6.0% | +7.7% | −20.8% | — | — | 29.5% | +3.0% |
| EMLP Broad MarketFirst Trust North American Energy Infrastructure Fund | 0.41 | +101% | 1.04 | +33.4% | +10.4% | −25.3% | — | — | — | 29.8% | +0.9% |
| HDV Dividend & IncomeiShares Core High Dividend ETF | 0.48 | +83.3% | 1.00 | +14.1% | +7.1% | −0.3% | — | — | — | 29.9% | +0.3% |
| SMH TechnologyVanEck Semiconductor ETF | 0.44 | +323% | 0.97 | +39.1% | −33.5% | −0.3% | −44.7% | — | — | 32.1% | +4.8% |
| GLD CommoditiesSPDR Gold Shares | 0.29 | +126% | 0.96 | +26.7% | −0.8% | −10.7% | +4.9% | — | — | 29.6% | +1.6% |
| SPMO Broad MarketInvesco S&P 500 Momentum ETF | 0.46 | +136% | 0.93 | +45.8% | −10.4% | — | — | — | — | 30.6% | +2.0% |
| XLE EnergyState Street Energy Select Sector SPDR ETF | 0.13 | +177% | 0.93 | +5.6% | +64.4% | −21.5% | −39.0% | +18.1% | — | 29.6% | +2.8% |
| EWT TechnologyiShares MSCI Taiwan ETF | 0.37 | +153% | 0.89 | +16.1% | −28.9% | −12.9% | −45.3% | — | — | 30.7% | +2.2% |
Stocks
| Investment | Correlation | 5Y return | Sharpe | 2024 | 2022 | 2015 | 2008 | 1999 | 1997 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IDXX IDEXX Laboratories, Inc. (this page) | 1.00 | −13.1% | 0.10 | −25.5% | −38.0% | −1.6% | −38.5% | −40.1% | −11.6% | 35.6% | −3.4% |
| CAH Medical - DistributionCardinal Health, Inc. | 0.24 | +479% | 1.55 | +19.0% | +54.1% | +12.6% | −39.6% | −36.8% | +29.1% | 30.1% | +5.0% |
| CLS Hardware, Equipment & PartsCelestica Inc. | 0.22 | +3,143% | 1.47 | +215% | +1.3% | −6.0% | −20.5% | +350% | — | 33.0% | +16.4% |
| FIX Engineering & ConstructionComfort Systems USA, Inc. | 0.34 | +1,636% | 1.46 | +107% | +17.0% | +67.7% | −15.2% | −58.7% | — | 32.6% | +12.4% |
| MCK Medical - DistributionMcKesson Corporation | 0.11 | +413% | 1.44 | +23.7% | +51.8% | −4.5% | −40.4% | −71.3% | +96.3% | 29.4% | +4.6% |
| MPC Oil & Gas Refining & MarketingMarathon Petroleum Corporation | 0.20 | +690% | 1.41 | −4.0% | +86.6% | +17.4% | — | — | — | 30.4% | +6.9% |
Common questions
What was IDXX's worst drawdown?
IDXX's deepest decline since it began trading in 1991 was 73.1%, from October 2006 to June 2007. It was back at its old high within a month of the low.
What were IDXX's best and worst years?
Over 29 full calendar years, IDXX's best year was 2020, when it returned 91.4%. Its worst was 1999, with a return of -40.1%.
Is there a better investment than IDXX?
Among IDXX's popular alternatives, TMO, DGX and LH earned more than IDXX with less volatility over the past 5 years. TMO returned 2.9% a year at 27.8% volatility, against a loss of 2.8% a year at 35.7%. Looking beyond its popular alternatives, ORLY (specialty retail) and LLY (pharmaceuticals) earned more than IDXX with less volatility over the past 5 years. ORLY returned 15.9% a year at 23.4% volatility, against a loss of 2.8% a year at 35.7%.
Is IDXX more volatile than the S&P 500?
Yes. IDXX's volatility over the past 5 years was 35.7%, about twice the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, IDXX's return lands within 35.7% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.
What is IDXX's Sharpe ratio?
IDXX's Sharpe ratio over the past 5 years was 0.10, against 0.79 for the S&P 500, so IDXX earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.
How correlated is IDXX with the S&P 500?
Over the past 5 years, IDXX's monthly returns had a correlation of 0.68 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against IDXX instead: the lower it is, the more that option would diversify a IDXX holding.
What are the best alternatives to IDXX?
Of the 19 popular alternatives we compared, six outperformed IDXX in at least 3 of 5 short-term and 2 of 3 long-term timeframes, with dividends reinvested: VEEV, TMO and A.
Did IDXX outperform the S&P 500?
IDXX finished ahead of the S&P 500 (SPY) in 21 of 29 full calendar years. In 2025, it returned +63.6%, against +17.7% for the index.
How did IDXX do in stock market crashes?
IDXX fell less than the S&P 500 (SPY) in one of the ten major crashes it has traded through, and further in nine. The clearest case was the 2022 bear market, when IDXX fell 46.4% and the S&P 500 fell 24.5%.
What diversifies IDXX?
These had a low correlation with IDXX over the past 5 years and still earned a positive 5-year return: among large ETFs, DXJ (correlation 0.36), EMLP (correlation 0.41) and HDV (correlation 0.48); among large stocks, CAH (correlation 0.24), CLS (correlation 0.22) and FIX (correlation 0.34). A correlation near zero means the two have moved largely independently.
How we measure
- Short-term periods are 1M, 3M, 6M, YTD, 1Y; long-term periods are 3Y, 5Y, 10Y. An investment outperformed in a period when its total return, with dividends reinvested, was higher than IDXX's. Returns within 0.5 points or 3% of IDXX's, whichever is larger, count as a tie.
- "Qualified" means outperforming in at least 3 of 5 short-term periods and 2 of 3 long-term periods. "All-weather" means outperforming in every long-term period and all but one short-term period.
- Popular alternatives are the funds and stocks most often compared with this one. We include only those that trade today, are not leveraged or inverse, and hold at least $200 million.
- Volatility is the annualized standard deviation of daily returns over 5 years, a measure of how much the price typically swings in a year. The Sharpe ratio is the return above cash for each unit of that volatility.
- A decline, or drawdown, runs from a peak to the lowest close before the next high. The worst decline ever uses all the price history we have; comparisons between funds use the past 10 years so that younger funds are judged on the same stretch.
- Sector overlap is the share of assets two funds hold in the same sectors. Correlation and the mixed-portfolio figures use monthly returns.
- Upside and downside capture follow Morningstar's definition: the compound monthly return in the months the S&P 500 rose (or fell), divided by the S&P 500's compound return in those months. Beta measures how strongly monthly returns have moved with the S&P 500. All three use the same window for every investment.
- Figures are computed from daily adjusted prices and update after each trading day. Past performance does not predict future results.
More research
Popular alternatives to IDXX
VEEVVeeva Systems
TMOThermo Fisher Scientific
AAgilent Technologies
WATWaters
BDXBecton, Dickinson and Company
ABTAbbott Laboratories
DHRDanaher